These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1250 related items for PubMed ID: 20505154

  • 1. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 2. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
    Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M.
    J Natl Cancer Inst; 2006 Aug 16; 98(16):1142-57. PubMed ID: 16912267
    [Abstract] [Full Text] [Related]

  • 3. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.
    Haematologica; 2008 Jan 16; 93(1):57-66. PubMed ID: 18166786
    [Abstract] [Full Text] [Related]

  • 4. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, Sezer O.
    Exp Cell Res; 2009 Aug 15; 315(14):2471-8. PubMed ID: 19410573
    [Abstract] [Full Text] [Related]

  • 5. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ.
    Clin Cancer Res; 2003 Oct 01; 9(12):4570-7. PubMed ID: 14555532
    [Abstract] [Full Text] [Related]

  • 6. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE.
    Cancer Res; 2007 Feb 15; 67(4):1783-92. PubMed ID: 17308121
    [Abstract] [Full Text] [Related]

  • 7. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.
    Clin Cancer Res; 2007 Oct 01; 13(19):5942-51. PubMed ID: 17908991
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 10. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR.
    Eur J Haematol; 2010 Mar 01; 84(3):201-11. PubMed ID: 19929977
    [Abstract] [Full Text] [Related]

  • 11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 01; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 12. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ.
    Cancer Res; 2005 Jul 15; 65(14):6282-93. PubMed ID: 16024630
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 14. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA.
    Biochem Pharmacol; 2012 Jan 15; 83(2):207-17. PubMed ID: 22027222
    [Abstract] [Full Text] [Related]

  • 15. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
    LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC.
    Cancer Res; 2002 Sep 01; 62(17):4996-5000. PubMed ID: 12208752
    [Abstract] [Full Text] [Related]

  • 16. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J.
    J Pharmacol Exp Ther; 2008 Aug 01; 326(2):423-31. PubMed ID: 18502982
    [Abstract] [Full Text] [Related]

  • 17. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.
    Cancer Res; 2007 Mar 15; 67(6):2783-90. PubMed ID: 17363600
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, Shimizu N.
    Anticancer Drugs; 2007 Jul 15; 18(6):677-86. PubMed ID: 17762396
    [Abstract] [Full Text] [Related]

  • 19. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.
    Cancer Cell; 2005 Nov 15; 8(5):407-19. PubMed ID: 16286248
    [Abstract] [Full Text] [Related]

  • 20. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M.
    Leukemia; 2004 Aug 15; 18(8):1357-63. PubMed ID: 15190257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.